Novel JAK Inhibitors Under Investigation for IBD

preview_player
Показать описание

Although the rapidly expanding IBD treatment armamentarium offers vastly improved opportunities to achieve treatment goals, it may also complicate treatment decisions. Clinicians who care for patients with IBD must understand how to maximize current therapies and effectively integrate newer therapies as they emerge as well as how to utilize objective measures of response in high-risk patients in order to better align their treatment with current best practices.

© 2021 Imedex, an HMP Company
  1. HMP Education
Рекомендации по теме
Novel JAK Inhibitors 0:22:00

Novel JAK Inhibitors Under Investigation for IBD

Investigating the place 0:00:53

Investigating the place of JAK inhibitors in the treatment of myelofibrosis

Session sneak peek: 0:01:11

Session sneak peek: Where to place novel JAK inhibitors

Polycythemia Vera: Novel 0:05:28

Polycythemia Vera: Novel JAK Inhibitors

Novel therapies for 0:02:04

Novel therapies for myelofibrosis patients who have failed JAK inhibitors

Management of Myelofibrosis: 1:03:11

Management of Myelofibrosis: JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

Targeted therapies beyond 0:01:23

Targeted therapies beyond JAK inhibitors

Novel agents under 0:00:34

Novel agents under investigation in MPNs: MDM2, XPO1, and BET inhibitors

Looking beyond JAK 0:03:21

Looking beyond JAK inhibitors: novel targeted therapies and strategies for MPN treatment

What Are the 0:02:29

What Are the Long-Term Effects of JAK Inhibitors?

Should we move 0:00:59

Should we move beyond JAK inhibitors in MPNs?

Moving beyond JAK 0:01:47

Moving beyond JAK inhibitors: novel targets and pathways being explored for the treatment of MPNs

Strategies for Improving 0:45:53

Strategies for Improving IMID Outcomes: The Potential of JAK Inhibitors

Topical JAK Inhibitors 0:08:49

Topical JAK Inhibitors | Jonathan Silverberg

Risk-Adapted Treatment in 0:37:14

Risk-Adapted Treatment in Myelofibrosis: JAK Inhibitors and Novel Combination Therapies

My view on 0:19:04

My view on current and future use of JAK inhibitors for ET, PV, and MF

Mechanism of Action 0:03:15

Mechanism of Action of JAK Inhibitors

Update on JAK 0:25:13

Update on JAK Inhibitors for Myelofibrosis: There is more than one

How to Manage 0:25:15

How to Manage Side Effects of JAK Inhibitors for Mylofibrosis in the Clinical Practice

Clinical investigation of 0:03:18

Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias

ASCO 2015: Novel 0:06:31

ASCO 2015: Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Current research into 0:01:58

Current research into JAK inhibitors - specifially ruxolitinib, pacritinib, and momelotinib

JAK inhibitor treatment 0:06:20

JAK inhibitor treatment shows benefit for patients with interferonopathies

LS Podcast S5 0:25:59

LS Podcast S5 EP151 - The Science and Clinical Approach to JAK Inhibitors in Atopic Dermatitis

Комментарии
Автор

How does the signal inhibition gets into the cell nucleus, is there a peptide sequence that works as a nuclear localization signal? Thanks for sharing it, I wish you all success in your work!

salvadorhirth